- Platelet-Leukocyte aggregates and micro-particles promote thrombosis. The different kinds of cells can act together to promote thrombosis.
- We need drugs that target the endothelial cells. Endothelial cells expand hematopoietic stem and progenitor cells by angiocrine expression of Notch ligands.
- The first hematopoiesis occurs with the endothelium.
- The leukemia from MPNs is completely different from the normal leukemias. We need different treatments because the biology is different.
- The Chronic Myeloid Leukemia is triggered by the Philadelphia chromosome, so it is regarded as a different disease process from MPNs.
- JAK2 is not a “switch” that can be flipped on or off; it has at least 10 different mutations, which cause different disease results in patients.
- Despite all the advances, we still have a long way to go – do not be misled by where we are.
- For those of us taking warfarin (Coumadin), Dr. Weksler said that the newer anti-coagulants are “not there yet”. Some patients have tried Pradaxa and gone back to warfarin. Pradaxa must be taken twice a day consistently and this is problematic for many patients. She believes that we’ll have a better alternative in a few years.
- Much of the knowledge gained and progress made has occurred because patients before us and among us have shared their tissue samples, DNA, and whole selves for testing and clinical trials.
There was so much more covered. I hope this tempts you to watch the video when it is available online at the MPN Research Foundation